MICARDIS

LOE Approaching

telmisartan

NDAORALTABLET
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Clinical Trials (5)

NCT03205137N/AWithdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Started Jun 2022
0
Hypertension
NCT02183675Phase 1Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Started Jul 2014
36 enrolled
Healthy
NCT02079805Phase 4Completed

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Started Jun 2014
33 enrolled
Essential Hypertension Complicated by Type 2 Diabetes Mellitus
NCT02129192Phase 1Completed

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Started May 2014
72 enrolled
Healthy
NCT02121535Phase 1Completed

Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use

Started Apr 2014
72 enrolled
Healthy